Phase II anti-inflammatory and immune-modulating drugs for acute ischaemic stroke

Expert Opinion on Investigational Drugs

Volumn 24, Issue 5, 2015, Pages 623-643

  Smith, Craig J ^a,b   Denes, Adam ^b,c   Tyrrell, Pippa J ^a,b   Di Napoli, Mario ^d  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Acute ischaemic stroke; Anti inflammatory; Cerebral ischaemia; Inflammation; Translational research

Indexed keywords

ANTIINFLAMMATORY AGENT; CITALOPRAM; CYCLOSPORIN A; DONEPEZIL; FINGOLIMOD; GINSENOSIDE RD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; NATALIZUMAB; NORPHENAZONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; URIC ACID; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; DEVELOPMENTAL STAGE; EXTRACELLULAR MATRIX; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE; NEUROPROTECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; REVIEW; STROKE UNIT; THROMBOCYTE; WHITE MATTER INJURY; ADULT; ANIMAL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; STROKE; TRANSLATIONAL RESEARCH;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN ISCHEMIA; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84927649035     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1020110     Document Type: Review

References (151)

1. Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245-54
2. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000;31:1240-9
3. Emberson J, Lees KR, Lyden P, et al. for the Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384(9958):1929-35
4. Koennecke HC, Belz W, Berfelde D, et al. for the Berlin Stroke Register Investigators. Factors influencing inhospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011;77:965-72
5. Finlayson O, Kapral M, Hall R, et al. on behalf of the Investigators of the Registry of the Canadian Stroke Network. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. Neurology 2011;77:1338-45
6. Westendorp WF, Nederkoorn PJ, Vermeij JD, et al. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol 2011;11:110
7. Emsley HC, Smith CJ, Gavin CM, et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003;139:93-101
8. Tuttolomondo A, Pinto A, Corrao S, et al. Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis. Atherosclerosis 2009;203:503-8
9. Emsley HC, Smith CJ, Gavin CM, et al. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol 2007;7:5
10. Haeusler KG, Schmidt WU, Föhring F, et al. Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis 2008;25:50-8
11. Prass K, Meisel C, Höflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003;198:725-36
12. Smith CJ, Emsley HC, Udeh CT, et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine 2012;58:384-9
13. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 2001;32:917-24
14. Smith CJ, Emsley HC, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004;4:2
15. Hug A, Dalpke A, Wieczorek N, et al. Infarct volume is a major determiner of post-stroke immune cell function and susceptibility to infection. Stroke 2009;40:3226-32
16. Scherbakov N, Dirnagl U, Doehner W. Body weight after stroke: lessons from the obesity paradox. Stroke 2011;42:3646-50
17. Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 1986;292:21-3
18. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 1996;27:1453-8
19. Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology 2001;57:1428-34
20. Bogousslavsky J, Victor SJ, Salinas EO, et al. European-Australian Fiblast (Trafermin) in Acute Stroke Group. Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis 2002;14:239-51
21. Krams M, Lees KR, Hacke W, et al. for the ASTIN Study. Acute stroke therapy by inhibition of neutrophils (ASTIN). An adaptive dose-response study of UK-279, 276 in acute ischhemic stroke. Stroke 2003;34:2543-8
22. Shauib A, Lees KR, Lyden P, et al. SAINT II. Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562-71
23. Ehrenreich H, Weissenborn K, Prange H, et al. EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56
24. den Hertog HM, van der Worp HB, van Gemert HM, et al. PAIS Investigators. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebocontrolled, phase III trial. Lancet Neurol 2009;8:434-40
25. Dávalos A, Alvarez-Sabiń J, Castillo J, et al. International Citicoline Trial on acUte Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebocontrolled study (ICTUS trial). Lancet 2012;380:349-57
26. Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial (NeuMAST). Available from: http:// clinicaltrials.gov/show/NCT00930020
27. Kohler E, Prentice DA, Bates TR, et al. Intravenous minocycline in acute stroke: a randomized, controlled pilot study and meta-analysis. Stroke 2013;44:2493-9
28. Ringelstein EB, Thijs V, Norrving B, et al. AXIS 2 Investigators. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke 2013;44:2681-7
29. Ginsberg MD, Palesch YY, Hill MD, et al. ALIAS and Neurological Emergencies Treatment Trials (NETT) Investigators. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, doubleblind, phase 3, placebo-controlled trial. Lancet Neurol 2013;12:1049-58
30. A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke. Available from: https://clinicaltrials.gov/ ct2/show/NCT00046761?term=arundic +acid&rank=6
31. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-8
32. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598-606
33. Fisher M; for the Stroke Therapy Academic Industry Roundtable. Recommendations for advancing development of acute stroke therapies. Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34:1539-46
34. Fisher M; for the Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies. Stroke Therapy Academic Industry Roundtable. Stroke 2005;36:1808-13
35. Fisher M, Feuerstein G, Howells DW, et al. for the STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-50
36. Saver JL, Albers GW, Dunn B, et al. for the STAIR VI Consortium. Stroke therapy academic industry roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 2009;40:2594-600
37. Wang J, Dor-e S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2007;27:894-908
38. Ovbiagele B, Hills NK, Saver JL, et al. for the California Acute Stroke Prototype Registry Investigators. Frequency and determinants of pneumonia and urinary tract infection during stroke hospitalization. J Stroke Cerebrovasc Dis 2006;15:209-13
39. Minnerup J, Schäbitz W. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 2009;6:43-52
40. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-50
41. Boutin H, LeFeuvre RA, Horai R, et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001;21:5528-34
42. Denes A, Pinteaux E, Rothwell NJ, et al. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc Dis 2011;32:517-27
43. Denes A, Wilkinson F, Bigger B, et al. Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice. Dis Model Mech 2013;6:1043-8
44. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005;5:629-40
45. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007;27:4403-12
46. Pradillo JM, Denes A, Greenhalgh AD, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 2012;32:1810-19
47. Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab 2011;31:439-47
48. Greenhalgh AD, Galea J, Denes A, et al. Rapid brain penetration of interleukin-1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection. Br J Pharmacol 2010;160:153-9
49. Singh N, Hopkins SJ, Hulme S, et al. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation 2014;11:1
50. Banwell V, Sena ES, Macleod MR. Systematic review and stratified metaanalysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis 2009;18:269-76
51. Emsley HCA, Smith CJ, Georgiou RF, et al. for the IL-1ra in Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76:1366-72
52. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5
53. Kawashima S, Yamashita T, Miwa Y, et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke 2003;34:157-63
54. Kilic U, Bassetti CL, Kilic E, et al. Post-ischemic delivery of the 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience 2005;134:901-6
55. Prinz V, Laufs U, Gertz K, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008;39:433-8
56. Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003;23:322-7
57. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-51
58. Baryan H, Vail A, Allan SM, et al. Systematic review and meta-analysis of the efficacy of statins in experimental stroke. Int J Stroke 2012;7:150-6
59. Krauth D, Anglemyer A, Philipps R, et al. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol 2014;12:e1001770
60. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60
61. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
62. Yokoi H, Nohara R, Daida H, et al. for the Justification of Atherosclerosis Regression Treatment (JART) Investigators. Changes in carotid intimamedia thickness in a high-risk group of patients by intensive lipid-lowering therapy with rosuvastatin. Subanalysis of the JART study. Int Heart J 2014;55:146-52
63. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering - are they clinically relevant? Eur Heart J 2003;24:225-48
64. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-201
65. Antonopoulos AS, Margaritis M, Shirodaria C, et al. Translating the effects of statins: from redox regulation to suppression of vascular wall inflammation. Thromb Haemost 2012;108:840-8
66. Di Napoli M, Papa F. Inflammation, statins, and outcome after ischemic stroke. Stroke 2001;32:2446-7
67. Montecucco F, Mach F. Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2009;23:389-400
68. Montecucco F, Quercioli A, Mirabelli-Badenier M, et al. Statins in the treatment of acute ischemic stroke. Curr Pharm Biotechnol 2012;13:68-76
69. Chróiniń N, Asplund K, Åsberg S, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational and randomized trials. Stroke 2013;44:448-56
70. Goldstein LB, Amarenco P, Zivin J, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009;40:3526-31
71. Montaner J, Chacoń P, Krupinski J, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol 2008;15:82-90
72. Szczepans̈ka-Szerej A, Kurzepa J, Wojczal J, et al. Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke. Pharmacol Rep 2007;59:94-7
73. Kurzepa J, Bielewicz J, Bartosik-Psujek H, et al. Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke. Pharmacol Rep 2008;60:1014-18
74. Elkind MS, Sacco R, MacArthur RB, et al. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009;28:266-75
75. Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): a Phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke. The Internet Stroke Center Trials Registry. Available from: http://www.strokecenter.org/trials/ clinicalstudies/neuroprotection-withstatin- therapy-for-acute-recovery-trialneu- starta-phase-2-safety-and-pilotefficacy- study-of-lovastatin-for-thetreatment- of-acute-ischemic-strokespotrias/ references
76. Muscari A, Puddu GM, Santoro N, et al. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. Clin Neuropharmacol 2011;34:141-7
77. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69:759-77
78. Rolland WB, Lekic T, Krafft PR, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol 2013;241:45-55
79. Campos F, Qin T, Castillo J, et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke 2013;44:505-11
80. Liu J, Zhang C, Tao W, et al. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int J Neurosci 2013;123:163-9
81. Kraft P, Göb E, Schuhmann MK, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thromboinflammation but not by direct neuroprotection. Stroke 2013;44:3202-10
82. Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf 2014;13:989-98
83. Espinera AR, Ogle ME, Gu X, et al. Citalopram enhances neurovascular regeneration and sensorimotor functional recovery after ischemic stroke in mice. Neuroscience 2013;247:1-11
84. Wang SS, Wang YG, Chen HY, et al. Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats. Neuro Endocrinol Lett 2013;34:773-9
85. Rodriguez-Grande B, Blackabey V, Gittens B, et al. Loss of substance P and inflammation precede delayed neurodegeneration in the substantia nigra after cerebral ischemia. Brain Behav Immun 2013;29:51-61
86. Kronenberg G, Balkaya M, Prinz V, et al. Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biol Psychiatry 2012;72:273-81
87. Wang T, Lv P, Jin W, et al. Protective effect of donepezil hydrochloride on cerebral ischemia/reperfusion injury in mice. Mol Med Rep 2014;9:509-14
88. Min D, Mao X, Wu K, et al. Donepezil attenuates hippocampal neuronal damage and cognitive deficits after global cerebral ischemia in gerbils. Neurosci Lett 2012;510:29-33
89. Fujiki M, Kobayashi H, Uchida S, et al. Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Brain Res 2005;1043:236-41
90. Yuan H, Wang WP, Feng N, et al. Donepezil attenuated oxygen-glucose deprivation insult by blocking Kv2.1 potassium channels. Eur J Pharmacol 2011;657:76-83
91. Akasofu S, Sawada K, Kosasa T, et al. Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to veratridine. Eur J Pharmacol 2008;588:189-97
92. Iwasaki K, Egashira N, Hatip-Al- Khatib I, et al. Cerebral ischemia combined with beta-amyloid impairs spatial memory in the eight-arm radial maze task in rats. Brain Res 2006;1097:216-23
93. Lee JH, Park SY, Shin YW, et al. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 2007;1185:246-55
94. Sakamoto K, Ohki K, Saito M, et al. Histological protection by donepezil against neurodegeneration induced by ischemia-reperfusion in the rat retina. J Pharmacol Sci 2010;112:327-35
95. Yoshiyama Y, Kojima A, Ishikawa C, et al. Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 2010;22:295-306
96. Cheyuo C, Jacob A, Wu R, et al. The parasympathetic nervous system in the quest for stroke therapeutics. J Cereb Blood Flow Metab 2011;31:1187-95
97. Barrett KM, Brott TG, Brown RD Jr, et al. Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) Study Group. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. J Stroke Cerebrovasc Dis 2011;20:177-82
98. Akdemir G, Ergungor MF, Sezer M, et al. Therapeutic efficacy of intraventricular cyclosporine A and methylprednisolone on a global cerebral ischemia model in rats. Neurol Res 2005;27:827-34
99. Chauhan A, Sharma U, Jagannathan NR, et al. Rapamycin protects against middle cerebral artery occlusion induced focal cerebral ischemia in rats. Behav Brain Res 2011;225:603-9
100. Cho TH, Aguettaz P, Campuzano O, et al. Pre- and post-treatment with cyclosporine A in a rat model of transient focal cerebral ischaemia with multimodal MRI screening. Int J Stroke 2013;8:669-74
101. Wakita H, Tomimoto H, Akiguchi I, et al. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke 1995;26:1415-22
102. Matsumoto S, Isshiki A, Watanabe Y, et al. Restricted clinical efficacy of cyclosporin A on rat transient middle cerebral artery occlusion. Life Sci 2002;72:591-600
103. Gill RS, Lee TF, Liu JQ, et al. Cyclosporine treatment reduces oxygen free radical generation and oxidative stress in the brain of hypoxiareoxygenated newborn piglets. PLoS One 2012;7:e40471
104. Peterson JW, Nishizawa S, Hackett JD, et al. Cyclosporine A reduces cerebral vasospasm after subarachnoid hemorrhage in dogs. Stroke 1990;21:133-7
105. Waring WS. Uric acid: an important antioxidant in acute ischaemic stroke. QJM 2002;95:691-3
106. Kanemitsu H, Tamura A, Kirino T, et al. Allopurinol inhibits uric acid accumulation in the rat brain following focal cerebral ischemia. Brain Res 1989;499:367-70
107. Tayag EC, Nair SN, Wahhab S, et al. Cerebral uric acid increases following experimental traumatic brain injury in rat. Brain Res 1996;733:287-91
108. Yu ZF, Bruce-Keller AJ, Goodman Y, et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res 1998;53:613-25
109. Romanos E, Planas AM, Amaro S, et al. Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007;27:14-20
110. Glantz L, Avramovich A, Trembovler V, et al. Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia. Exp Neurol 2005;192:117-24
111. Kobayashi T, Kouzaki H, Kita H. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J Immunol 2010;184:6350-8
112. Kono H, Chen CJ, Ontiveros F, et al. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 2010;120:1939-49
113. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One 2011;6:e19901
114. Savage CD, Lopez-Castejon G, Denes A, et al. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol 2012;3:288
115. Chamorro A, Obach V, Cervera A, et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002;33:1048-52
116. Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951
117. Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007;38:2173-5
118. Amaro S, Obach V, Cervera A, et al. Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol 2009;256:651-6
119. Chamorro A, Amaro S, Castellanos M, et al. URICO-ICTUS Investigators. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol 2014;13:453-60
120. Coisne C, Mao W, Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J Immunol 2009;182:5909-13
121. Liesz A, Zhou W, Mracsko E, et al. Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 2011;134:704-20
122. Relton JK, Sloan KE, Frew EM, et al. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke 2001;32:199-205
123. Langhauser F, Kraft P, Gob E, et al. Blocking of alpha4 integrin does not protect from acute ischemic stroke in mice. Stroke 2014;45:1799-806
124. Ye R, Zhao G, Liu X. Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside. Expert Rev Neurother 2013;13:603-13
125. Ye R, Kong X, Yang Q, et al. Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window. Neurotherapeutics 2011;8:515-25
126. Ye R, Yang Q, Kong X, et al. Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. Neurochem Int 2011;58:391-8
127. Hu G, Wu Z, Yang F, et al. Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-kB nuclear accumulation by inhibiting poly(ADPribose) polymerase-1 after focal cerebral ischemia in rats. Neurol Sci 2013;34:2101-6
128. Zhou Y, Li HQ, Lu L, et al. Ginsenoside Rg1 provides neuroprotection against blood brain barrier disruption and neurological injury in a rat model of cerebral ischemia/reperfusion through downregulation of aquaporin 4 expression. Phytomedicine 2014;21:998-1003
129. Liu X, Xia J, Wang L, et al. Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, doubleblind, placebo-controlled, phase II multicenter trial. Eur J Neurol 2009;16:569-75
130. Liu X, Wang L, Wen A, et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial. Eur J Neurol 2012;19:855-63
131. Ahmad A, Khan MM, Javed H, et al. Edaravone ameliorates oxidative stress associated cholinergic dysfunction and limits apoptotic response following focal cerebral ischemia in rat. Mol Cell Biochem 2012;367:215-25
132. Xiao B, Bi FF, Hu YQ, et al. Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats. Neurotox Res 2007;12:155-62
133. Yagi K, Kitazato KT, Uno M, et al. Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke 2009;40:626-31
134. Zhang W, Sato K, Hayashi T, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res 2004;26:342-8
135. Srinivasan K, Sharma SS. Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. Basic Clin Pharmacol Toxicol 2011;110:133-40
136. Kern R, Nagayama M, Toyoda K, et al. Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 2013;35:402-18
137. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-9
138. Zhang M, Xu L, Deng L, et al. Efficacy and safety evaluation of edaravone injection in treatment of acute cerebral infarction: a multicentre, double-blind, and randomized controlled clinical trial. Chinese J New Drugs Clin Remedies 2007;26:105-8
139. Zhou M, Yang J, He L. Randomized controlled trial of edaravone injection in the treatment of acute cerebral infarction. Mod Prev Med 2007;34:966-8
140. Shinohara Y, Saito I, Kobayashi S, et al. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis 2009;27:485-92
141. Feng S, Yang Q, Liu M, et al. Edaravone for acute ischaemic stroke. Cochrane Database Syst Rev 2011(12):CD007230
142. Kaste M, Murayama S, Ford GA, et al. MCI-186 study group. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis 2013;36:196-204
143. O'Collins VE, Macleod MR, Donnan GA, et al. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77
144. Smith CJ, Lawrence CB, Rodriguez-Grande B, et al. The immune system in stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol 2013;8:867-87
145. Bailey EL, McCulloch J, Sudlow C, et al. Potential animal models of lacunar stroke: a systematic review. Stroke 2009;40:e451-8
146. Crossley NA, Sena E, Goehler J, et al. Empirical evidence of bias in the design of experimental stroke studies: a metaepidemiologic approach. Stroke 2008;39:929-34
147. Dirnagl U, Hakim A, Macleod M, et al. A concerted appeal for international cooperation in preclinical stroke research. Stroke 2013;44:1754-60
148. Albers GW, Goldstein LB, Hess DC, et al. STAIR VII Consortium. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke 2011;42:2645-50
149. Yeatts SD. Novel approaches to phase I, II and III trials. Stroke 2013;44:s116-18
150. Bath PM, Lees KR, Schellinger PD, et al. European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012;43:1171-8
151. Nair SB, Dileep A, Rajanikant GK. Nanotechnology based diagnostic and therapeutic strategies for neuroscience with special emphasis on ischemic stroke. Curr Med Chem 2012;19:744-56